Patents by Inventor Christoph Hoenke

Christoph Hoenke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS
    Publication number: 20240342186
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: June 5, 2024
    Publication date: October 17, 2024
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Cédrickx GODBOUT, Christian GNAMM, Patrick GROSS, Marc Alexander GRUNDL, Joerg Thomas KLEY, Christian Andreas KUTTRUFF, Dirk REINART, Raphael STUBER, Theodor THEIS
  • [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4
    Publication number: 20240327429
    Abstract: The present disclosure provides [1,3]thiazolo[4,5-d]-pyrimidon-7-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: February 27, 2024
    Publication date: October 3, 2024
    Inventors: Christian GNAMM, Elmar BAUSCHATZ, Frank BUETTNER, Cédrickx GODBOUT, Annekatrin Charlotte HEIMANN, Christoph HOENKE, Ferenc KONTES, Christian Andreas KUTTRUFF, Dieter WIEDENMAYER, Raphael WILDERMUTH
  • Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors
    Patent number: 12043625
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: July 23, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Annekatrin Charlotte Heimann, Sandra Ruth Handschuh, Christoph Hoenke, Christian Gnamm, Cédrickx Godbout, Patrick Gross, Joerg Kley, Christian Andreas Kuttruff, Dirk Reinert, Raphael Stuber, Marc Grundl, Theodor Theis
  • CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS
    Publication number: 20240208997
    Abstract: The invention relates to compounds of formula I wherein R1, R2, R3, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: November 3, 2023
    Publication date: June 27, 2024
    Inventors: Annekatrin Charlotte HEIMANN, Alexander DREYER, Christian GNAMM, Cédrickx GODBOUT, Marc Alexander GRUNDL, Sandra Ruth HANDSCHUH, Christoph HOENKE, Joerg Thomas KLEY, Christian Andreas KUTTRUFF, Jun LI, Dirk REINERT, Raphael STUBER
  • Cyclic Pyridine Derivatives as cGAS Inhibitors
    Publication number: 20240189315
    Abstract: The invention relates to compounds of formula I wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: November 3, 2023
    Publication date: June 13, 2024
    Inventors: Annekatrin Charlotte HEIMANN, Christian GNAMM, Cédrickx GODBOUT, Sandra Ruth HANDSCHUH, Christoph HOENKE, Joerg Thomas KLEY, Christian Andreas KUTTRUFF, Jun LI, Dirk REINERT, Raphael STUBER, Theodor THEIS
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20240109909
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 4, 2024
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
    Publication number: 20230286993
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of formula (I) wherein R1, R2, R3, R5, R6 and A are as defined herein. The compounds of formula (1) are inhibitors of phosphodiesterase 2 and useful in treating central nervous system diseases and other diseases. The invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11731981
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: August 22, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide
    Patent number: 11691977
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors
    Patent number: 11583532
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS
    Publication number: 20230000878
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Cédrickx GODBOUT, Christian GNAMM, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER
  • PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS
    Publication number: 20230002401
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Christian GNAMM, Cédrickx GODBOUT, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER
  • Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11254688
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220002310
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 6, 2022
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11046706
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • BENZYL-, (PYRIDIN-3-YL)METHYL -OR (PYRIDIN-4-YL)-METHYL-SUBSTIITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210053985
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 25, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210038603
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
    Publication number: 20210032259
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
    Patent number: 10875867
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
    Publication number: 20200039991
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON